KR102072268B1 - 디하이드로피리다진-3,5-디온 유도체 - Google Patents
디하이드로피리다진-3,5-디온 유도체 Download PDFInfo
- Publication number
- KR102072268B1 KR102072268B1 KR1020167027514A KR20167027514A KR102072268B1 KR 102072268 B1 KR102072268 B1 KR 102072268B1 KR 1020167027514 A KR1020167027514 A KR 1020167027514A KR 20167027514 A KR20167027514 A KR 20167027514A KR 102072268 B1 KR102072268 B1 KR 102072268B1
- Authority
- KR
- South Korea
- Prior art keywords
- substituted
- alkyl
- alkoxy
- phenyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC[C@](C(C(C*)=C=*)=C(*C)C1(CC)C=C*1C)N Chemical compound CC[C@](C(C(C*)=C=*)=C(*C)C1(CC)C=C*1C)N 0.000 description 12
- LHZAENXXJJSGHR-UHFFFAOYSA-N Bc1cc(OCCOC)c(C(F)(F)F)cc1 Chemical compound Bc1cc(OCCOC)c(C(F)(F)F)cc1 LHZAENXXJJSGHR-UHFFFAOYSA-N 0.000 description 1
- HQUZEIBCNYJCFX-NSCUHMNNSA-N C/C=C/NCCS Chemical compound C/C=C/NCCS HQUZEIBCNYJCFX-NSCUHMNNSA-N 0.000 description 1
- ZAPUGMTZFAFQMT-UHFFFAOYSA-N CC1(C(OC)=O)NCCCC1 Chemical compound CC1(C(OC)=O)NCCCC1 ZAPUGMTZFAFQMT-UHFFFAOYSA-N 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N CC1CCCC1 Chemical compound CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- CEJWKANZZDRDPE-BOFKRWBFSA-N CC1OC[C@@H](COC/C=C/S)O/C1=C\C Chemical compound CC1OC[C@@H](COC/C=C/S)O/C1=C\C CEJWKANZZDRDPE-BOFKRWBFSA-N 0.000 description 1
- KXEAPTKIGYWRFL-GCZGRYASSA-N CCCCCN[NH+](/C(/C(OC)=O)=C(\[C@]1(C)NCCC1)/O)[O-] Chemical compound CCCCCN[NH+](/C(/C(OC)=O)=C(\[C@]1(C)NCCC1)/O)[O-] KXEAPTKIGYWRFL-GCZGRYASSA-N 0.000 description 1
- LLUHXQZGXOMQQU-OEAKJJBVSA-N CN(CCOC)CCOc(ccc(/C=N/N(C)C1(CCC1)C(OC)=O)c1F)c1F Chemical compound CN(CCOC)CCOc(ccc(/C=N/N(C)C1(CCC1)C(OC)=O)c1F)c1F LLUHXQZGXOMQQU-OEAKJJBVSA-N 0.000 description 1
- CSIPMPYXUPIYEG-BUVRLJJBSA-N CN(CCOC)CCOc(ccc(/C=N/N(C)C1(CCCC1)C(OC)=O)c1F)c1F Chemical compound CN(CCOC)CCOc(ccc(/C=N/N(C)C1(CCCC1)C(OC)=O)c1F)c1F CSIPMPYXUPIYEG-BUVRLJJBSA-N 0.000 description 1
- XDTMAHQUMYJHDR-UHFFFAOYSA-N CN(CCOC)CCOc(cccc1F)c1F Chemical compound CN(CCOC)CCOc(cccc1F)c1F XDTMAHQUMYJHDR-UHFFFAOYSA-N 0.000 description 1
- IHIJKZYDEDKOQN-UHFFFAOYSA-N CN(CCOC)CCOc1ccc(CN(C(CC(Nc2ccc(C(F)(F)F)cc2-c2ncnc(C(F)(F)F)c2)=O)=O)N(C)C2(CCC2)C(OC)=O)c(F)c1F Chemical compound CN(CCOC)CCOc1ccc(CN(C(CC(Nc2ccc(C(F)(F)F)cc2-c2ncnc(C(F)(F)F)c2)=O)=O)N(C)C2(CCC2)C(OC)=O)c(F)c1F IHIJKZYDEDKOQN-UHFFFAOYSA-N 0.000 description 1
- MISXNAQMZZCFST-UHFFFAOYSA-N COCCOc(c(C(F)(F)F)c1)cc(N)c1-c(cccc1OC)c1OC Chemical compound COCCOc(c(C(F)(F)F)c1)cc(N)c1-c(cccc1OC)c1OC MISXNAQMZZCFST-UHFFFAOYSA-N 0.000 description 1
- UVGVAYJKKHTYCH-JGCGQSQUSA-N C[C@@](CCC1)(C(N)=C2C(Nc(ccc(C(F)(F)F)c3)c3-c(cc3NC)cnc3N3CCOCC3)=O)N1N(Cc1cccc(F)c1F)C2=O Chemical compound C[C@@](CCC1)(C(N)=C2C(Nc(ccc(C(F)(F)F)c3)c3-c(cc3NC)cnc3N3CCOCC3)=O)N1N(Cc1cccc(F)c1F)C2=O UVGVAYJKKHTYCH-JGCGQSQUSA-N 0.000 description 1
- FHNCCYWKTKDDPE-FAOTXVLUSA-N C[C@@](CCC1)(C(O)=C2C(Nc3c(C4NC=NC(C(F)(F)F)=C4)cc(C(F)(F)F)cc3)=O)N1N(CC(C1F)=CCCC1F)C2=O Chemical compound C[C@@](CCC1)(C(O)=C2C(Nc3c(C4NC=NC(C(F)(F)F)=C4)cc(C(F)(F)F)cc3)=O)N1N(CC(C1F)=CCCC1F)C2=O FHNCCYWKTKDDPE-FAOTXVLUSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Luminescent Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013051082 | 2013-03-13 | ||
| JPJP-P-2013-051082 | 2013-03-13 | ||
| JP2013132889 | 2013-06-25 | ||
| JPJP-P-2013-132889 | 2013-06-25 | ||
| PCT/JP2014/056778 WO2014142273A1 (ja) | 2013-03-13 | 2014-03-13 | ジヒドロピリダジン－３，５－ジオン誘導体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157029079A Division KR101664460B1 (ko) | 2013-03-13 | 2014-03-13 | 디하이드로피리다진-3,5-디온 유도체 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160119282A KR20160119282A (ko) | 2016-10-12 |
| KR102072268B1 true KR102072268B1 (ko) | 2020-01-31 |
Family
ID=51536921
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167027514A Active KR102072268B1 (ko) | 2013-03-13 | 2014-03-13 | 디하이드로피리다진-3,5-디온 유도체 |
| KR1020157029079A Active KR101664460B1 (ko) | 2013-03-13 | 2014-03-13 | 디하이드로피리다진-3,5-디온 유도체 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157029079A Active KR101664460B1 (ko) | 2013-03-13 | 2014-03-13 | 디하이드로피리다진-3,5-디온 유도체 |
Country Status (29)
| Country | Link |
|---|---|
| EP (2) | EP2975030B1 (https=) |
| JP (2) | JP5814488B2 (https=) |
| KR (2) | KR102072268B1 (https=) |
| CN (1) | CN105073715B (https=) |
| AU (1) | AU2014230552B2 (https=) |
| BR (1) | BR112015022092B1 (https=) |
| CA (1) | CA2901868C (https=) |
| CL (1) | CL2015002543A1 (https=) |
| CR (1) | CR20150505A (https=) |
| DK (1) | DK2975030T3 (https=) |
| ES (1) | ES2811126T3 (https=) |
| HR (1) | HRP20201211T1 (https=) |
| HU (1) | HUE050577T2 (https=) |
| IL (1) | IL240825B (https=) |
| LT (1) | LT2975030T (https=) |
| MX (1) | MX376532B (https=) |
| MY (1) | MY174269A (https=) |
| NZ (1) | NZ711182A (https=) |
| PE (1) | PE20151535A1 (https=) |
| PH (1) | PH12015501940B1 (https=) |
| PL (1) | PL2975030T3 (https=) |
| PT (1) | PT2975030T (https=) |
| RS (1) | RS60911B1 (https=) |
| RU (1) | RU2662832C2 (https=) |
| SG (1) | SG11201507345RA (https=) |
| SI (1) | SI2975030T1 (https=) |
| TW (2) | TWI683811B (https=) |
| UA (1) | UA118755C2 (https=) |
| WO (1) | WO2014142273A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2975030T (pt) * | 2013-03-13 | 2020-09-28 | Chugai Pharmaceutical Co Ltd | Derivado de di-hidropiridazina-3,5-diona |
| NZ729640A (en) * | 2014-09-12 | 2022-04-29 | Chugai Pharmaceutical Co Ltd | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor |
| WO2018019721A1 (en) | 2016-07-26 | 2018-02-01 | Basf Se | Herbicidal pyridine compounds |
| WO2018019755A1 (en) | 2016-07-26 | 2018-02-01 | Basf Se | Herbicidal pyridine compounds |
| CN110885290A (zh) * | 2019-12-16 | 2020-03-17 | 阿里生物新材料（常州）有限公司 | 一种3-氟-2-甲基-4-三氟甲基苯胺盐酸盐的合成方法 |
| KR20230033708A (ko) * | 2020-06-26 | 2023-03-08 | 니혼노야쿠가부시키가이샤 | 아릴테트라히드로피리다진 유도체 또는 그의 염류 및 해당 화합물을 함유하는 살충제 그리고 그 사용 방법 |
| WO2022221182A1 (en) * | 2021-04-12 | 2022-10-20 | Jnana Therapeutics Inc. | Small molecule inhibitors of mammalian slc34a1 function |
| AR126060A1 (es) | 2021-06-08 | 2023-09-06 | Chugai Pharmaceutical Co Ltd | Método para producir derivado de dihidropiridazin-3,5-diona |
| KR20240018523A (ko) | 2021-06-08 | 2024-02-13 | 추가이 세이야쿠 가부시키가이샤 | 다이하이드로피리다진-3,5-다이온 유도체를 함유하는 제제 |
| CA3244263A1 (en) | 2021-12-28 | 2025-06-13 | Nihon Nohyaku Co., Ltd. | ARYL TETRAHYDROPYRIDAZINE DERIVATIVE OR SALT THEREOF, PESTICIDE CONTAINING SAID COMPOUND AND ASSOCIATED METHOD OF USE |
| WO2023219127A1 (ja) | 2022-05-11 | 2023-11-16 | 中外製薬株式会社 | 嚢胞性疾患を治療または予防するための医薬組成物 |
| CN116217862A (zh) * | 2023-03-21 | 2023-06-06 | 中国农业科学院农业环境与可持续发展研究所 | 一种可降解生物膜助剂的制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010009183A1 (en) | 2008-07-16 | 2010-01-21 | Bristol-Myers Squibb Company | Pyridone and pyridazone analogues as gpr119 modulators |
| WO2010022240A1 (en) | 2008-08-20 | 2010-02-25 | Fibrogen, Inc. | Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators |
| WO2011048611A1 (en) | 2009-10-07 | 2011-04-28 | Torrent Pharmaceuticals Limited | Novel fused pyridazine derivatives |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2292337C2 (ru) * | 2002-02-19 | 2007-01-27 | Оно Фармасьютикал Ко., Лтд. | Конденсированные производные пиридазина и лекарственные препараты, содержащие данные соединения в качестве активного ингредиента |
| CN1662529A (zh) * | 2002-06-19 | 2005-08-31 | 默克专利有限公司 | 作为磷酸二酯酶iv抑制剂的噻唑衍生物 |
| SG177981A1 (en) * | 2005-05-18 | 2012-02-28 | Array Biopharma Inc | 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases |
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| WO2008053043A1 (de) * | 2006-11-03 | 2008-05-08 | Basf Se | Verfahren zur herstellung von difluormethylpyrazolylcarboxylaten |
| PL2565190T3 (pl) | 2010-04-28 | 2015-10-30 | Astellas Pharma Inc | Związek tetrahydrobenzotiofenowy |
| WO2012006475A1 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| JP5827327B2 (ja) * | 2010-07-07 | 2015-12-02 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| ES2585415T3 (es) | 2011-10-27 | 2016-10-05 | Astellas Pharma Inc. | Derivado de N-tienilbenzamida sustituida con aminoalquilo |
| PT2975030T (pt) * | 2013-03-13 | 2020-09-28 | Chugai Pharmaceutical Co Ltd | Derivado de di-hidropiridazina-3,5-diona |
-
2014
- 2014-03-13 PT PT147656193T patent/PT2975030T/pt unknown
- 2014-03-13 ES ES14765619T patent/ES2811126T3/es active Active
- 2014-03-13 KR KR1020167027514A patent/KR102072268B1/ko active Active
- 2014-03-13 NZ NZ711182A patent/NZ711182A/en unknown
- 2014-03-13 CN CN201480013485.6A patent/CN105073715B/zh active Active
- 2014-03-13 MX MX2015012537A patent/MX376532B/es active IP Right Grant
- 2014-03-13 HU HUE14765619A patent/HUE050577T2/hu unknown
- 2014-03-13 WO PCT/JP2014/056778 patent/WO2014142273A1/ja not_active Ceased
- 2014-03-13 MY MYPI2015703054A patent/MY174269A/en unknown
- 2014-03-13 JP JP2015505576A patent/JP5814488B2/ja active Active
- 2014-03-13 PE PE2015001917A patent/PE20151535A1/es unknown
- 2014-03-13 DK DK14765619.3T patent/DK2975030T3/da active
- 2014-03-13 UA UAA201509770A patent/UA118755C2/uk unknown
- 2014-03-13 EP EP14765619.3A patent/EP2975030B1/en active Active
- 2014-03-13 HR HRP20201211TT patent/HRP20201211T1/hr unknown
- 2014-03-13 EP EP20185235.7A patent/EP3757093A1/en active Pending
- 2014-03-13 PL PL14765619T patent/PL2975030T3/pl unknown
- 2014-03-13 LT LTEP14765619.3T patent/LT2975030T/lt unknown
- 2014-03-13 AU AU2014230552A patent/AU2014230552B2/en active Active
- 2014-03-13 CA CA2901868A patent/CA2901868C/en active Active
- 2014-03-13 SG SG11201507345RA patent/SG11201507345RA/en unknown
- 2014-03-13 RU RU2015143507A patent/RU2662832C2/ru active
- 2014-03-13 RS RS20201171A patent/RS60911B1/sr unknown
- 2014-03-13 TW TW106123450A patent/TWI683811B/zh active
- 2014-03-13 KR KR1020157029079A patent/KR101664460B1/ko active Active
- 2014-03-13 BR BR112015022092-4A patent/BR112015022092B1/pt active IP Right Grant
- 2014-03-13 SI SI201431629T patent/SI2975030T1/sl unknown
- 2014-03-13 TW TW103109058A patent/TWI596095B/zh active
-
2015
- 2015-08-25 IL IL240825A patent/IL240825B/en active IP Right Grant
- 2015-09-03 PH PH12015501940A patent/PH12015501940B1/en unknown
- 2015-09-09 CL CL2015002543A patent/CL2015002543A1/es unknown
- 2015-09-16 JP JP2015182722A patent/JP6420738B2/ja active Active
- 2015-09-22 CR CR20150505A patent/CR20150505A/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010009183A1 (en) | 2008-07-16 | 2010-01-21 | Bristol-Myers Squibb Company | Pyridone and pyridazone analogues as gpr119 modulators |
| WO2010022240A1 (en) | 2008-08-20 | 2010-02-25 | Fibrogen, Inc. | Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators |
| WO2011048611A1 (en) | 2009-10-07 | 2011-04-28 | Torrent Pharmaceuticals Limited | Novel fused pyridazine derivatives |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102072268B1 (ko) | 디하이드로피리다진-3,5-디온 유도체 | |
| KR102431216B1 (ko) | 나트륨 의존성 인산 트랜스포터 저해제를 함유하는 의약 | |
| CN114805303A (zh) | 一种具有降解egfr双功能分子及其组合物和药学上的应用 | |
| WO2014146490A1 (en) | Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors | |
| US9499553B2 (en) | Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same | |
| RU2811864C1 (ru) | Фармацевтическое средство, содержащее ингибитор натрийзависимого переносчика фосфата | |
| EP4479407A1 (en) | Substituted bicyclic heteroaryl compounds useful as inhibitors of tlr9 | |
| HK1212700B (en) | Dihydropyridazine-3,5-dione derivative | |
| HK1235279A1 (en) | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PX0901 | Re-examination |
St.27 status event code: A-2-3-E10-E12-rex-PX0901 |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| FPAY | Annual fee payment |
Payment date: 20221207 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 7 |